DxB-062 Inclusion: Standard Inclusion Criteria: • Subjects 18 years of age or older. • Subjects who have provided prior written informed consent to participate may be included in this Study • Diagnosed with stage IV M1b or stage IV M1c NSCLC cancer by a licensed physician Specific Inclusion Requirements for subjects collected under the AJCC 7th edition staging guidelines: • Cohort 1: Primary treatment naïve NSCLC patients (prior to surgery, chemotherapy or any other treatment) • Cohort 2: Recurrent NSCLC patients: o one year without chemotherapy o 6 months without radiation o Patients are not on any treatment at the time of the blood draw o Example: If a patient was diagnosed with primary stage I-III NSCLC previously, was treated for it and was in remission (one year without chemo or 6 months without radiation); then got diagnosed with a metastatic stage IV M1b NSCLC or stage IV M1c. Such patient can be enrolled prior to administration of the treatment for the metastatic stage of the disease. • Cohort 3: Primary or Recurrent NSCLC patients progressed to stage IV M1b or M1c while on current treatment (chemotherapy). Enroll no more than 16 patients in this cohort. o Blood to be collected prior to the start of the new treatment o Blood to be collected at any time after the end of the current treatment as long as the patient has not yet started a new therapy Per AJCC 8th Edition: • Stage IV M1b NSCLC patients: o The primary lesion is >7 cm • Stage IV M1c NSCLC patients: o radiographic evidence of disseminated disease involving multiple organs. Specific Inclusion Requirements for subjects collected under the AJCC 8th edition staging guidelines: • Cohort 1: Primary treatment naïve NSCLC patients (prior to surgery, chemotherapy or any other treatment) • Cohort 2: Recurrent NSCLC patients: o one year without chemotherapy o 6 months without radiation o Patients are not on any treatment at the time of the blood draw o Example: If a patient was diagnosed with primary stage I-III NSCLC previously, was treated for it and was in remission (one year without chemo or 6 months without radiation); then got diagnosed with a metastatic stage IV M1c NSCLC. Such patient can be enrolled prior to administration of the treatment for the metastatic stage of the disease. • Cohort 3: Primary or Recurrent NSCLC patients progressed to stage IV M1c while on current treatment (chemotherapy). Enroll no more than 16 patients in this cohort. o Blood to be collected prior to the start of the new treatment o Blood to be collected at any time after the end of the current treatment as long as the patient has not yet started a new therapy DxB-093 Inclusion: • Primary PD1/PDL1 treatment naïve NSCLC patients • Other primary treatments are accepted : surgery, chemotherapy or any other non IO treatment • Subject is to begin a PD1/PDL1 treatment, baseline collection MUST be done prior to PD1/PDL1 treatment initiation • Subjects 18 years of age or older. • Subjects who have provided prior written informed consent to participate may be included in this Study • Subject has agreed to participate in the two timepoint research collection • Diagnosed with any stage NSCLC cancer by a licensed physician DxB-118 Inclusion: • Male subjects, ≥ 18 years of age • Subject must have histologically confirmed diagnosis of metastatic castrate resistant prostate cancer (mCRPC) • Subjects 18 years of age or older. • Subjects who have provided prior written informed consent to participate may be included in this Study • Diagnosed with mCRPC by a licensed physician • Pathologically confirmed DxB-120 Inclusion: Standard Inclusion Criteria: • Subjects 18 years of age or older. • Subjects who have provided prior written informed consent to participate may be included in this Study • Diagnosed with stage IV cancer by a licensed physician Specific Inclusion Criteria: • Subject must be diagnosed with Stage IV Disease in these Cancer types: o NSCLC, CRC, Prostate, Ovarian, Breast, GI (Non-CRC), Hepato-Pancreatobiliary, Urinary, Endocrine, Skin (Melanoma, Sarcoma) • Subjects MUST be o COHORT 1: Primary Treatment Naïve; collected prior to surgery, chemo, or any other treatment OR o COHORT 2: Recurrent Patients who are treatment naïve for the metastatic stage of disease Cohort 2 for Prostate cancer patients : -patients progressed from M0 to M1 and are now metastatic -must be castrate resistant -Can be on hormone therapy but must be naïve to other treatments for metastatic stage (M1) of disease DxB-149 Standard Inclusion Criteria: • Subjects 18 years of age or older. • Subjects who have provided prior written informed consent to participate may be included in this Study • Diagnosed with Metastatic Breast cancer (stage IV) by a licensed physician Specific Inclusion Criteria: Subject must be diagnosed with Metastatic Breast Cancer, with active (newly diagnosed) OR progressing disease ER+; 20 subjects to enroll, includes: ER+/PR-/HER2- ER+/PR+/HER2- ER-/PR+/HER2- HER2+; 20 subjects to enroll, includes: Any ER/PR status combination/HER2+ o Triple Negative Breast Cancer (TNBC) includes: ER-/PR-/HER2- • Subjects MUST be (in order of preference) o Primary Treatment Naïve; collected prior to surgery, chemo, or any other treatment OR o Recurrent Patients who are treatment naïve for the metastatic stage of disease OR o Patients currently receiving treatment with evidence of disease progression DxB-172 Standard Inclusion Criteria: • Subjects 18 years of age or older. • Subjects who have provided prior written informed consent to participate may be included in this Study • Diagnosed clinically or pathologically with Stage III or Stage IV NSCLC by a licensed physician Specific Inclusion Criteria: • Subject must be diagnosed with NSCLC, Stage III or Stage IV o Primary or Recurrent o NSCLC Adenocarcinoma preferred  However, if a different histology is confirmed, then the sample will be acceptable • Subjects MUST be (in order of preference) o Primary Treatment Naïve; collected prior to surgery, chemo, or any other treatment OR o Patients currently receiving treatment with evidence of disease progression/Non responsive to treatment  Patients must be between lines of treatment at the time of the blood draw. Preferably with at least a washout period of 2 weeks • Flexible if this becomes prohibitive to collections. DxB-175 Standard Inclusion Criteria: • Subjects 18 years of age or older. • Subjects who have provided prior written informed consent to participate may be included in this Study • Diagnosed by a licensed physician Specific Inclusion Criteria: • Subject must be diagnosed with one of these Cancer types: o Colorectal Cancer (4 subjects) o Non-Small Cell Lung Cancer (4 subjects) o Breast Cancer (4 subjects) o Ovarian Cancer (4 subjects) o Prostate Cancer (4 subjects) • Primary and/or recurrent diagnosis acceptable • Any Stage is acceptable • Subjects can be Treatment Naïve, Previously Treated, OR Currently receiving Treatment o There is no inclusion/exclusion treatment criteria; for example: treatment types, length of treatment cycles, etc. o Subjects receiving treatment with stable/non-progressing disease are acceptable DxB-177 Specific Inclusion Criteria: • Subject must be diagnosed with Metastatic Stage IV Cancer: o Non-Small Cell Lung Cancer o Colorectal Cancer o Prostate Cancer • Subjects can be treatment naïve or recurrent with treatment history (Cont) • If Subjects have treatment history, subject MUST be: o Recurrent Patients who are treatment naïve for the metastatic Stage IV stage of disease OR o Patients currently receiving treatment with evidence of disease progression, samples must be collected PRIOR to the initiation of new line of treatment  Wash out period of 1-week for non-oral treatments OTHER than Radiation (no washout required for radiation therapy) • Non-oral treatments include: surgery, chemotherapy, immunotherapy, other IV treatments  NO wash out period needed for oral treatments; including oral chemotherapy, immunotherapy, hormonal therapy, etc Standard Inclusion Criteria: • Subjects 18 years of age or older. • Subjects who have provided prior written informed consent to participate may be included in this Study • Diagnosed with Metastatic Stage IV NSCLC, CRC or Prostate Cancer by a licensed physician DxB-178 Specific Inclusion Requirements: • Any stage Primary Treatment naïve NSCLC patients OR Recurrent Treatment Naïve NSCLC patients o Primary Treatment Naïve: newly diagnosed, prior to receiving ANY treatment OR o Recurrent Treatment Naïve: patient has NOT received any treatment for at least 2 years • If patient is undergoing surgery for SUSPECTED NSCLC, this subject will be accepted into the study Standard Inclusion Criteria: • Subjects 18 years of age or older. • Subjects who have provided prior written informed consent to participate may be included in this Study • Diagnosed with any stage NSCLC cancer by a licensed physician DxB-184 Specific Inclusion Requirements: • Subjects Diagnosed with Stage III or Stage IV NSCLC • Disease can be primary or recurrent • Subjects MUST be immunotherapy treatment naïve, with plans to begin an IO treatment o Other primary treatments are accepted: surgery, radiation, chemotherapy or any other non-IO treatment • Subject’s treatment plan should include immunotherapy treatment initiation Standard Inclusion Criteria: • Subjects 18 years of age or older. • Subjects who have provided prior written informed consent to participate may be included in this Study • Subject has agreed to participate in the specimen collection and follow up data captures • Diagnosed with any stage NSCLC cancer by a licensed physician DxB-233 Specific Inclusion • Diagnosed with Stage III or IV Cancer o Any cancer type is acceptable o No gender or race restrictions o Primary or Recurrent cancers acceptable o Prior history of cancer is acceptable, IF NOT WITHIN 5 years • Subjects must be Treatment Naïve or Previously Treated o Subjects not on any treatment / treatment naïve at time of collection are PREFFERED o Pre-resection subjects are preferred  Post-resection subjects who have not started chemo or radiation are acceptable  Surgically excised subjects are acceptable, if confirmed staging and treatment status o Subjects receiving treatment with evidence of disease progression are acceptable; HOWEVER samples must be collected PRIOR to the initiation of new line of treatment.  Wash out period of 1-week for non-oral treatments. Non-oral treatments include: surgery, chemotherapy, immunotherapy, other IV treatments  No wash out period needed for oral treatments; including oral chemotherapy, immunotherapy, hormonal therapy, etc.  No wash out period needed for radiation therapy or injectables (such as Lupron or Casodex Standard Inclusion • Subjects 18 years of age or older. • Subjects who have provided prior written informed consent to participate may be included in this Study • Diagnosed with Stage III or IV Cancer by a licensed physician DxB-240 Specific Inclusion • Diagnosed with Stage III or IV Cancer o Subjects newly diagnosed or recently diagnosed are PREFFERED o Primary or Recurrent cancers acceptable o No gender or race restrictions o Prior history of cancer is acceptable, IF NOT WITHIN 5 years • Any cancer type is acceptable; At least one (1) subject for each of the following cancer types: o Colorectal o Breast o Ovarian o Lung o Prostate • Subjects not on any treatment (Treatment Naïve) or Previously Treated are PREFFERED o Subjects receiving treatment with evidence of disease progression acceptable; HOWEVER, samples must be collected within one month of the start of treatment o Pre-resection subjects are preferred  Post-resection subjects who have not started chemo or radiation are acceptable  Surgically excised subjects are acceptable, if confirmed staging and treatment status Standard Inclusion • Subjects 18 years of age or older. • Subjects who have provided prior written informed consent to participate may be included in this Study • Diagnosed with Stage III or IV Cancer by a licensed physician

 

DxB-062 Exclusion: • Younger than 18 years of age • History of Blood Borne Diseases including HIV, HCV, HBV, and syphilis: o History of HIV, HBV, HCV and syphilis in the subject’s chart o Subject verbally confirmed that he/she is HIV, HBV, HCV and syphilis positive. • Patients who are pregnant, lactating, or generally not healthy enough for blood donation should be excluded. • Subjects who have not provided prior written informed consent to participate may not be included in this Study. DxB-093 Exclusion: • Younger than 18 years of age • History of Blood Borne Diseases including HIV, HCV, HBV, and syphilis: o History of HIV, HBV, HCV and syphilis in the subject’s chart o Subject verbally confirmed that he/she is HIV, HBV, HCV and syphilis positive. • Patients who are pregnant, lactating, or generally not healthy enough for blood donation should be excluded. • Subjects who have not provided prior written informed consent to participate may not be included in this Study. DxB-118 Exclusion: • Females • Subjects younger than 18 years of age • Male Subjects without histologic confirmation of mCRPC • History of Blood Borne Diseases including HIV, HCV, HBV, and syphilis: o History of HIV, HBV, HCV and syphilis in the subject’s chart o Subject verbally confirmed that he/she is HIV, HBV, HCV and syphilis positive. • Patients who are generally not healthy enough for blood donation should be excluded. • Subjects who have not provided prior written informed consent to participate may not be included in this Study. DxB-120 Exclusion: • Subjects diagnosed with stage of disease other than Stage IV • Subjects who have received treatment for their primary disease • Subjects who have received treatment for their recurrent disease • Younger than 18 years of age • History of Blood Borne Diseases including HIV, HCV, HBV, and syphilis: o History of HIV, HBV, HCV and syphilis in the subject’s chart o Subject verbally confirmed that he/she is HIV, HBV, HCV and syphilis positive. • Patients who are pregnant, lactating, or generally not healthy enough for blood donation should be excluded. • Subjects who have not provided prior written informed consent to participate may not be included in this Study. DxB-149 Exclusion • Subjects diagnosed with stage of disease other than Stage IV • Subjects with stable disease o Subject not progressing on current treatment o Subjects who are receiving maintenance therapy • Subjects who are in remission must be excluded • Younger than 18 years of age • History of Blood Borne Diseases including HIV, HCV, HBV, and syphilis: o History of HIV, HBV, HCV and syphilis in the subject’s chart o Subject verbally confirmed that he/she is HIV, HBV, HCV and syphilis positive. • Patients who are pregnant, lactating, or generally not healthy enough for blood donation should be excluded. • Subjects who have not provided prior written informed consent to participate may not be included in this Study. DxB-172 • Subjects diagnosed with stage of disease other than Stage III or Stage IV • Subjects with stable disease o Subject not progressing on current treatment o Subjects who are receiving maintenance therapy • Subjects who are in remission must be excluded • Younger than 18 years of age • History of Blood Borne Diseases including HIV, HCV, HBV, and syphilis: o History of HIV, HBV, HCV and syphilis in the subject’s chart o Subject verbally confirmed that he/she is HIV, HBV, HCV and syphilis positive. • Patients who are pregnant, lactating, or generally not healthy enough for blood donation should be excluded. • Subjects who have not provided prior written informed consent to participate may not be included in this Study. DxB-175 Specific Exclusion Criteria: • Subjects diagnosed with disease other than what is listed in inclusion Standard Exclusion Criteria: • Younger than 18 years of age • History of Blood Borne Diseases including HIV, HCV, HBV, and syphilis: o History of HIV, HBV, HCV and syphilis in the subject’s chart o Subject verbally confirmed that he/she is HIV, HBV, HCV and syphilis positive. • Patients who are pregnant, lactating, or generally not healthy enough for blood donation should be excluded. • Subjects who have not provided prior written informed consent to participate may not be included in this Study. DxB-177 Specific Exclusion Criteria: • Subjects diagnosed with stage of disease other than Stage IV o Subjects with mets to the Lymph Nodes (stages II – III) will NOT be accepted • Subjects with stable disease o Subject not progressing on current treatment o Subjects who are receiving maintenance therapy • Subjects who are in remission must be excluded Standard Exclusion Criteria: • Younger than 18 years of age • History of Blood Borne Diseases including HIV, HCV, HBV, and syphilis: o History of HIV, HBV, HCV and syphilis in the subject’s chart o Subject verbally confirmed that he/she is HIV, HBV, HCV and syphilis positive. • Patients who are pregnant, lactating, or generally not healthy enough for blood donation should be excluded. • Subjects who have not provided prior written informed consent to participate may not be included in this Study. DxB-178 Specific Exclusion Criteria: • Patients currently receiving treatment • Patients in remission • Recurrent NSCLC patients who are less than 2 years since receiving treatment Standard Exclusion Criteria: • Younger than 18 years of age • History of Blood Borne Diseases including HIV, HCV, HBV, and syphilis: o History of HIV, HBV, HCV and syphilis in the subject’s chart o Subject verbally confirmed that he/she is HIV, HBV, HCV and syphilis positive. • Patients who are pregnant, lactating, or generally not healthy enough for blood donation should be excluded. • Subjects who have not provided prior written informed consent to participate may not be included in this Study. DxB-184 Specific Exclusion Requirements: • Subjects Diagnosed with Stage I or Stage II NSCLC • Subjects who are NOT Immunotherapy treatment naïve o Current or a history of immunotherapy • Subjects who are NOT to begin immunotherapy treatment Standard Exclusion Criteria: • Younger than 18 years of age • History of Blood Borne Diseases including HIV, HCV, HBV, and syphilis: o History of HIV, HBV, HCV and syphilis in the subject’s chart o Subject verbally confirmed that he/she is HIV, HBV, HCV and syphilis positive. • Patients who are pregnant, lactating, or generally not healthy enough for blood donation should be excluded. • Subjects who have not provided prior written informed consent to participate may not be included in this Study. DxB-233 Specific Exclusion • Subjects NOT diagnosed with Stage III or IV Cancer • Subjects diagnosed with hematologic malignancies • Subjects diagnosed with concurrent cancer Standard Exclusion Criteria • Subjects younger than 18 years of age. • History of Blood Borne Diseases including HIV, HCV, HBV, and syphilis: o History of HIV, HBV, HCV and syphilis in the subject’s chart o Subject verbally confirmed that he/she is HIV, HBV, HCV and syphilis positive. • Pregnant, lactating, or subjects who are not healthy enough for blood donation. • Subjects who have not provided prior written informed consent to participate. DxB-240 Specific Exclusion Criteria: • Subjects NOT diagnosed with Stage III or IV Cancer • Subjects diagnosed with hematologic malignancies • Subjects diagnosed with concurrent cancer • Subjects who are in remission • Subjects with partial responses should be excluded Standard Exclusion Criteria: • Subjects younger than 18 years of age. • History of Blood Borne Diseases including HIV, HCV, HBV, and syphilis: o History of HIV, HBV, HCV and syphilis in the subject’s chart o Subject verbally confirmed that he/she is HIV, HBV, HCV and syphilis positive. • Pregnant, lactating, or subjects who are not healthy enough for blood donation. • Subjects who have not provided prior written informed consent to participate.